0.31
+0.0025(+0.81%)
Currency In USD
| Previous Close | 0.31 |
| Open | 0.31 |
| Day High | 0.31 |
| Day Low | 0.3 |
| 52-Week High | 2.54 |
| 52-Week Low | 0.22 |
| Volume | 1.36M |
| Average Volume | 1.17M |
| Market Cap | 19.36M |
| PE | -0.43 |
| EPS | -0.73 |
| Moving Average 50 Days | 0.33 |
| Moving Average 200 Days | 0.48 |
| Change | 0 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $24.46 as of July 01, 2025 at a share price of $0.312. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $138.8 as of July 01, 2025 at a share price of $0.312.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
GlobeNewswire Inc.
11 hours ago
PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study su
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
GlobeNewswire Inc.
Jun 25, 2025 11:30 AM GMT
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, In
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Jun 03, 2025 11:30 AM GMT
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (N